KDx Diagnostics Inc. and UroGPO Announce a Partnership to Offer the URO17® NON-INVASIVE Urine Test for Bladder Cancer in the United States

SAN JOSE, Calif. and CLEVELAND, May 27, 2022 /PRNewswire/ -- KDx Diagnostics and UroGPO announced today the partnership to provide the URO17® test (Research Use Only in the US) for the detection of bladder cancer. URO17® is a non-invasive urine test with high sensitivity and negative...

Click to view original post